Literature DB >> 3182445

Sub-inhibitory and post-antibiotic effects of spiramycin and erythromycin on Staphylococcus aureus.

C Webster1, K Ghazanfar, R Slack.   

Abstract

The antibacterial responses of clinical isolates of Staphylococcus aureus to spiramycin and erythromycin were compared. Conventional MICs showed erythromycin-sensitive strains to be 16-32 times less sensitive to spiramycin. MBCs were only four to eight times higher for spiramycin. Erythromycin resistant S. aureus were more frequently encountered. Concentrations of both macrolides at 1/4 MIC produced antibacterial effects. Post-antibiotic effects were more marked with spiramycin. After 3 h exposure to 4 x MIC of antibiotic the delay in regrowth of S. aureus was 5 h for erythromycin and 9 h for spiramycin. In a continuous cultivation model, spiramycin produced an inhibitory effect on S. aureus for 12 h whereas the effect of erythromycin was only apparent for 6 h. In conclusion, spiramycin is more active against staphylococci in vitro than would be expected by its modest MICs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3182445     DOI: 10.1093/jac/22.supplement_b.33

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Flow cytometric assessment of the postantibiotic effect of methicillin on Staphylococcus aureus.

Authors:  M T Suller; D Lloyd
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 2.  Pharmacodynamics and pharmacokinetics of spiramycin and their clinical significance.

Authors:  I Brook
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

3.  Molecular investigation of the postantibiotic effects of clarithromycin and erythromycin on Staphylococcus aureus cells.

Authors:  W S Champney; C L Tober
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

Review 4.  Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides.

Authors:  G G Zhanel; W A Craig
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

5.  Efficacy of spiramycin as an alternative to amoxicillin in the treatment of acute upper respiratory tract infections.

Authors:  C Bunnag; P Jareoncharsri; S Voraprayoon; A Vitavasiri; P Supatchaipisit; S Kongpatanakul
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.